Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 1/2008

01-02-2008

A benchmark comparison across USA anticoagulation centers using the dawn anticoagulation software

Authors: Syd Stewart, Louise Pearson

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2008

Login to get access

Excerpt

The Dawn AC Benchmarking Service currently has 81 sites World-wide participating with over 212,000 patients and over 1,720,000 INRs. The nine participating USA centers are compared against an average of the top five centers World-wide in the table below for the 2.5 target and stable patients (22+ weeks of treatment):
Center
% Time in range
% Below range
% Above range
% INRs >5
% INRs <1.3
% Manual dose interventions
% Test interval interventions
Top 5 average
77.3
13.0
9.7
0.5
2.3
17.5
27.0
1
75.1
16.7
8.1
0.7
1.1
15.5
17.5
2
71.9
11.9
16.3
1.2
2.0
27.8
32.5
3
69.0
17.7
13.3
1.1
2.9
34.4
49.0
4
65.6
21.0
13.4
1.3
3.7
20.9
39.4
5
65.4
17.3
17.3
2.1
4.0
54.4
51.7
6
64.2
20.3
15.5
1.3
3.9
33.5
51.7
7
63.6
22.2
14.2
1.3
4.1
24.9
29.0
8
62.2
24.4
13.4
1.3
2.8
33.5
29.4
9
61.7
24.8
13.5
1.6
4.1
22.1
23.1
Metadata
Title
A benchmark comparison across USA anticoagulation centers using the dawn anticoagulation software
Authors
Syd Stewart
Louise Pearson
Publication date
01-02-2008
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2008
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-007-0150-5

Other articles of this Issue 1/2008

Journal of Thrombosis and Thrombolysis 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.